copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Home | Harrow, Inc. Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
Harrow Announces First-Quarter 2025 Financial Results Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
Corporate Presentation November 2025 - harrow. com Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
Careers | Harrow, Inc. At Harrow, we’re always interested in connecting with talented, purpose-driven, and mission-minded individuals who share our passion for advancing eye health and improving patients’ lives
Quarterly Results | Harrow, Inc. The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
www. harrow. com harrow health inc-2 harrow health inc-1 harrow health inc Harrow Health INC 2,145,767 shares of common stock available for award under the Company’s 2017 Incentive Stock and Awards Plan (the “Plan) as of March 31, 2023;
www. harrow. com and market launch Supporting Studies: In support of an NDA filing, Harrow will be initiating one non-clinical animal study and three PK studies to generate the balance of the data necessary for an NDA package NDA Submission (H1 2027): Prepare and submit the NDA for MELT-300